"10.1371_journal.pone.0050317","plos one","2012-11-27T00:00:00Z","Alfred T Welzel; Angela D Williams; Helen P McWilliams-Koeppen; Luis Acero; Alfred Weber; Veronika Blinder; Alex Mably; Sebastian Bunk; Corinna Hermann; Michael A Farrell; Hartmut J Ehrlich; Hans P Schwarz; Dominic M Walsh; Alan Solomon; Brian O’Nuallain","The Conway Institute, University College Dublin, Belfield, Dublin, Republic of Ireland; Human Immunology and Cancer Program, Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, Tennessee, United States of America; Baxter BioScience, Vienna, Austria; The Laboratory of Neurodegenerative Research, Brigham and Womens Hospital, Harvard Institutes of Medicine, Boston, Massachusetts, United States of America; Dublin Brain Bank, Pathology Department, Beaumont Hospital, Dublin, Ireland","Conceived and designed the experiments: BO AS ATW DMW. Performed the experiments: BO ATW ADW HPM LA VB AM SB CH. Analyzed the data: BO ATW ADW HPM LA VB AM DMW SB CH. Contributed reagents/materials/analysis tools: AW MAF HJE HPS DMW. Wrote the paper: BO.","This work was supported in part by funding from Baxter BioScience, the employer of AW, HJE and HPS, and the European Community 7th Framework Programme (FP7/2007–2013) under grant agreement No. 200611 (DMW). Intravenous immunoglobulin (IVIg; Gammagard liquid®) was provided by Baxter BioScience (Vienna, Austria), and is a Baxter Bioscience product. BO has served as a member of a Baxter preclinical Scientific Advisory Board. DMW is a consultant, shareholder and member of the scientific advisory board of Senexis plc. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2012","11","Alfred T Welzel","ATW",15,TRUE,4,9,10,1,TRUE,TRUE,FALSE,0,NA,FALSE
